Zobrazeno 1 - 10
of 117
pro vyhledávání: '"Masanobu, Sato"'
Autor:
Masanobu Sato, Tomohiro Enokida, Takao Fujisawa, Susumu Okano, Naohiro Takeshita, Nobukazu Tanaka, Hideki Tanaka, Atsushi Motegi, Sadamoto Zenda, Takeshi Shinozaki, Kazuto Matsuura, Ryuichi Hayashi, Tetsuo Akimoto, Makoto Tahara
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundThe significance of induction chemotherapy (IC) in the treatment of squamous cell carcinoma of the head and neck (SCCHN) with unresectable locoregional recurrence after curative surgery has not been clarified. The aim of this study was to e
Externí odkaz:
https://doaj.org/article/5697b67731264e01bfe02545996835e8
Autor:
Yuta Hoshi, Tomohiro Enokida, Shingo Tamura, Torahiko Nakashima, Susumu Okano, Takao Fujisawa, Masanobu Sato, Akihisa Wada, Hideki Tanaka, Naohiro Takeshita, Nobukazu Tanaka, Ryutaro Onaga, Takuma Kishida, Hideoki Uryu, Shingo Sakashita, Takahiro Asakage, Makoto Tahara
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundOlfactory neuroblastoma (ONB) is a rare malignant tumor of the head and neck. Due to its rarity, standard systemic therapy for this condition has yet to be established. In particular, the use of immune checkpoint inhibitors (ICIs) for the r
Externí odkaz:
https://doaj.org/article/159b1d1219d8410983fabd24393b33ea
Autor:
Hideki Tanaka, Tomohiro Enokida, Susumu Okano, Takao Fujisawa, Nobukazu Tanaka, Naohiro Takeshita, Ryutaro Onaga, Yuta Hoshi, Akihisa Wada, Masanobu Sato, Yuri Ueda, Makoto Tahara
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundImmune checkpoint inhibitors (ICIs) are essential in treating recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). However, the overall response rate (ORR) is limited to 10-20%, and subsequent chemotherapy is criti
Externí odkaz:
https://doaj.org/article/ba07fb074d6240e3bcd6832f75fe358e
Autor:
Ryutaro Onaga, Tomohiro Enokida, Kazue Ito, Yuri Ueda, Susumu Okano, Takao Fujisawa, Akihisa Wada, Masanobu Sato, Hideki Tanaka, Naohiro Takeshita, Nobukazu Tanaka, Yuta Hoshi, Makoto Tahara
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundDespite advances in precision medicine, most patients with recurrent or metastatic salivary gland carcinoma still need conventional chemotherapies, such as the combination of taxane and platinum. However, evidence for these standardized reg
Externí odkaz:
https://doaj.org/article/4830b975dd4143c69ef643d2aa8f99b8
Autor:
Naohiro Takeshita, Tomohiro Enokida, Susumu Okano, Takao Fujisawa, Akihisa Wada, Masanobu Sato, Hideki Tanaka, Nobukazu Tanaka, Atsushi Motegi, Sadamoto Zenda, Tetsuo Akimoto, Makoto Tahara
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundThe addition of induction chemotherapy (IC) before chemoradiotherapy (CRT) has improved survival over CRT alone in locoregionally advanced nasopharyngeal cancer (LA-NPC). Nevertheless, this population would benefit from further development
Externí odkaz:
https://doaj.org/article/4a3174b19f0745039c5c2b3df20a3103
Autor:
Akihisa Wada, Tomohiro Enokida, Susumu Okano, Masanobu Sato, Hideki Tanaka, Yuri Ueda, Takao Fujisawa, Naohiro Takeshita, Nobukazu Tanaka, Makoto Tahara
Publikováno v:
European Journal of Cancer. 184:30-38
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0e9927931ec58ea8ad462b008331b1db
https://doi.org/10.1016/j.ejca.2023.02.011
https://doi.org/10.1016/j.ejca.2023.02.011
Autor:
Nobukazu Tanaka, Tomohiro Enokida, Takao Fujisawa, Susumu Okano, Akihisa Wada, Masanobu Sato, Hideki Tanaka, Naohiro Takeshita, Makoto Tahara
Publikováno v:
International Journal of Clinical Oncology. 27:1669-1674
Cetuximab (Cmab) plays an important role in the treatment for recurrent or metastatic head and neck cancer (R/M HNC). To date, however, no safety data on biweekly administration of cetuximab at a dose of 500 mg/mWe retrospectively reviewed the clinic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57d89f0c827f7f116a1ee4239d529b0f
https://doi.org/10.1007/s10147-022-02226-5
https://doi.org/10.1007/s10147-022-02226-5
Publikováno v:
BMJ case reports. 15(12)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3882a94046d66c4d0b43c5049e0eec7
https://pubmed.ncbi.nlm.nih.gov/36593619
https://pubmed.ncbi.nlm.nih.gov/36593619
Publikováno v:
Curriculum Studies in Health and Physical Education. 13:138-155
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a595398e13f8e7a43726a5c92c487b65
https://doi.org/10.1080/25742981.2021.1992291
https://doi.org/10.1080/25742981.2021.1992291
Autor:
Rina Jiromaru, Yui Nozaki, Takahiro Hongo, Takafumi Nakano, Azusa Sugii, Masanobu Sato, Minako Fujiwara, Hidetaka Yamamoto, Kenichi Taguchi, Kazuki Hashimoto, Yoshinao Oda
Publikováno v:
Human Pathology. 109:37-44
Salivary secretory carcinoma (SASC) is frequently associated with ETV6-neurotrophic tyrosine receptor kinase (NTRK) 3 fusion and more rarely with RET, MET, or ALK rearrangement. We aimed to elucidate the potential diagnostic utility of pan-tropomyosi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0e6446de6d48e60c3f89be8ecde70c0
https://doi.org/10.1016/j.humpath.2020.11.017
https://doi.org/10.1016/j.humpath.2020.11.017